{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T07:17:18Z","timestamp":1792048638415,"version":"4.4.0"},"reference-count":63,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,4,22]],"date-time":"2024-04-22T00:00:00Z","timestamp":1713744000000},"content-version":"vor","delay-in-days":477,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalmicrobiologyandinfection.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.cmi.2022.07.008","type":"journal-article","created":{"date-parts":[[2022,7,18]],"date-time":"2022-07-18T23:17:48Z","timestamp":1658186268000},"page":"13-21","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis"],"prefix":"10.1016","volume":"29","author":[{"given":"Arthur M.","family":"Albuquerque","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Eckert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Tramujas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guillaume","family":"Butler-Laporte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily G.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd C.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cmi.2022.07.008_bib1","doi-asserted-by":"crossref","DOI":"10.1016\/j.cmi.2022.04.018","article-title":"Remdesivir for the treatment of COVID-19: an updated systematic review and meta-analysis [e-pub ahead of print]","author":"Lee","year":"2022","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.cmi.2022.07.008_bib2","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1056\/NEJMoa2105911","article-title":"Therapeutic anticoagulation with heparin in noncritically ill patients with Covid-19","volume":"385","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib3","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/S0140-6736(22)00163-5","article-title":"Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"399","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.07.008_bib4","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1001\/jama.2020.17023","article-title":"Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: a meta-analysis","volume":"324","author":"Sterne","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.07.008_bib5","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.2021.11330","article-title":"Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: a meta-analysis","volume":"326","year":"2021","journal-title":"JAMA"},{"key":"10.1016\/j.cmi.2022.07.008_bib6","series-title":"Effectiveness of tocilizumab, sarilumab, and anakinra for critically ill patients with COVID-19 the REMAP-CAP COVID-19 immune modulation therapy domain randomized clinical trial","author":"Derde","year":"2021"},{"key":"10.1016\/j.cmi.2022.07.008_bib7","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus remdesivir for hospitalized adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib8","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib9","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2022.0548","article-title":"Mortality rates among hospitalized patients with COVID-19 infection treated with tocilizumab and corticosteroids: a Bayesian reanalysis of a previous meta-analysis","volume":"5","author":"Albuquerque","year":"2022","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cmi.2022.07.008_bib10","series-title":"Therapeutics and COVID-19 guideline development","author":"World Health Organization","year":"2022"},{"key":"10.1016\/j.cmi.2022.07.008_bib11","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib12","series-title":"Analysis plan: effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19: a systematic review and meta-regression","author":"Albuquerque","year":"2022"},{"key":"10.1016\/j.cmi.2022.07.008_bib13","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","article-title":"Rayyan\u2014a web and mobile app for systematic reviews","volume":"5","author":"Ouzzani","year":"2016","journal-title":"Syst Rev"},{"key":"10.1016\/j.cmi.2022.07.008_bib14","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib15","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib16","doi-asserted-by":"crossref","first-page":"n160","DOI":"10.1136\/bmj.n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib17","series-title":"Cochrane handbook for systematic reviews of interventions","year":"2022"},{"key":"10.1016\/j.cmi.2022.07.008_bib18","series-title":"Bayesian approaches to clinical trials and health care evaluation","author":"Spiegelhalter","year":"2004"},{"key":"10.1016\/j.cmi.2022.07.008_bib19","series-title":"Statistical rethinking: a bayesian course with examples in R and stan","author":"McElreath","year":"2020"},{"key":"10.1016\/j.cmi.2022.07.008_bib20","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1037\/1082-989X.3.4.486","article-title":"Fixed- and random-effects models in meta-analysis","volume":"3","author":"Hedges","year":"1998","journal-title":"Psychol Methods"},{"key":"10.1016\/j.cmi.2022.07.008_bib21","first-page":"1","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.cmi.2022.07.008_bib22","doi-asserted-by":"crossref","unstructured":"Higgins JPT, Thompson SG, Spiegelhalter DJ. A re-evaluation of random-effects meta-analysis. J R Stat Soc Ser A Stat Soc;172:137\u2013159.","DOI":"10.1111\/j.1467-985X.2008.00552.x"},{"key":"10.1016\/j.cmi.2022.07.008_bib23","series-title":"Small sample size solutions","first-page":"30","article-title":"A\u00a0tutorial on using the Wambs Checklist to avoid the misuse of Bayesian statistics","author":"van de Schoot","year":"2020"},{"key":"10.1016\/j.cmi.2022.07.008_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1177\/0962280215620828","article-title":"Performance of informative priors skeptical of large treatment effects in clinical trials: a simulation study","volume":"27","author":"Pedroza","year":"2018","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.cmi.2022.07.008_bib25","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib26","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1002\/jrsm.1475","article-title":"On weakly informative prior distributions for the heterogeneity parameter in Bayesian random-effects meta-analysis","volume":"12","author":"R\u00f6ver","year":"2021","journal-title":"Res Synth Methods"},{"key":"10.1016\/j.cmi.2022.07.008_bib27","doi-asserted-by":"crossref","first-page":"d4002","DOI":"10.1136\/bmj.d4002","article-title":"Recommendations for examining and interpreting funnel plot asymmetry in meta-analyses of randomised controlled trials","volume":"343","author":"Sterne","year":"2011","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib28","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1002\/sim.2971","article-title":"Arcsine test for publication bias in meta-analyses with binary outcomes","volume":"27","author":"R\u00fccker","year":"2008","journal-title":"Stat Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib29","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1136\/bmj.39489.470347.AD","article-title":"GRADE: an emerging consensus on rating quality of evidence and strength of recommendations","volume":"336","author":"Guyatt","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib30","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.jclinepi.2019.03.003","article-title":"Most noninferiority trials were not designed to preserve active comparator treatment effects","volume":"110","author":"Tsui","year":"2019","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.cmi.2022.07.008_bib31","series-title":"Non-inferiority clinical trials to establish effectiveness guidance for industry","year":"2016"},{"key":"10.1016\/j.cmi.2022.07.008_bib32","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1164\/rccm.202006-2381CP","article-title":"Using Bayesian methods to augment the interpretation of critical care trials. An overview of theory and example reanalysis of the alveolar recruitment for acute respiratory distress syndrome trial","volume":"203","author":"Zampieri","year":"2021","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib33","series-title":"Tocilizumab versus baricitinib in hospitalized patients with severe COVID- 19: an open label, randomized controlled trial","author":"Karampitsakos","year":"2022"},{"key":"10.1016\/j.cmi.2022.07.008_bib34","first-page":"1","article-title":"Stan: a probabilistic programming language","volume":"76","author":"Carpenter","year":"2017","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.cmi.2022.07.008_bib35","first-page":"1","article-title":"brms: an R package for Bayesian multilevel models using Stan","volume":"80","author":"B\u00fcrkner","year":"2017","journal-title":"J\u00a0Stat Softw"},{"key":"10.1016\/j.cmi.2022.07.008_bib36","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1037\/met0000065","article-title":"Improving transparency and replication in Bayesian statistics: the WAMBS-Checklist","volume":"22","author":"Depaoli","year":"2017","journal-title":"Psychol Methods"},{"key":"10.1016\/j.cmi.2022.07.008_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s43586-020-00001-2","article-title":"Bayesian statistics and modelling","volume":"1","author":"van de Schoot","year":"2021","journal-title":"Nat Rev Methods Primers"},{"key":"10.1016\/j.cmi.2022.07.008_bib38","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1007\/s11684-020-0824-3","article-title":"Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial","volume":"15","author":"Wang","year":"2021","journal-title":"Front Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib39","first-page":"24","article-title":"Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: a randomized clinical trial","volume":"181","author":"Salvarani","year":"2021","journal-title":"JAMA Intern"},{"key":"10.1016\/j.cmi.2022.07.008_bib40","doi-asserted-by":"crossref","first-page":"ofab608","DOI":"10.1093\/ofid\/ofab608","article-title":"Safety and efficacy of tocilizumab 4 or 8 mg\/kg in hospitalized patients with moderate to severe Coronavirus disease 2019 pneumonia: a randomized clinical trial","volume":"9","author":"Kumar","year":"2022","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.008_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0263591","article-title":"Subcutaneous sarilumab for the treatment of hospitalized patients with moderate to severe COVID19 disease: a pragmatic, embedded randomized clinical trial","volume":"17","author":"Branch-Elliman","year":"2022","journal-title":"PLoS ONE"},{"key":"10.1016\/j.cmi.2022.07.008_bib43","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19","volume":"384","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib44","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.cmi.2022.07.008_bib45","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1001\/jamainternmed.2020.6820","article-title":"Effect of tocilizumab vs usual care in adults hospitalized with COVID-19 and moderate or severe pneumonia: a randomized clinical trial","volume":"181","author":"Hermine","year":"2021","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib46","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1056\/NEJMoa2028700","article-title":"Tocilizumab in hospitalized patients with severe Covid-19 pneumonia","volume":"384","author":"Rosas","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib47","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1056\/NEJMoa2030340","article-title":"Tocilizumab in patients hospitalized with Covid-19 pneumonia","volume":"384","author":"Salama","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib48","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1056\/NEJMoa2028836","article-title":"Efficacy of tocilizumab in patients hospitalized with Covid-19","volume":"383","author":"Stone","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib49","doi-asserted-by":"crossref","first-page":"n84","DOI":"10.1136\/bmj.n84","article-title":"Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial","volume":"372","author":"Veiga","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib50","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1007\/s00134-021-06507-x","article-title":"Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial","volume":"47","author":"Rosas","year":"2021","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib51","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib52","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.02523-2021","article-title":"Effect of interleukin-6 receptor antagonists in critically ill adult patients with COVID-19 pneumonia: two randomised controlled trials of the CORIMUNO-19 Collaborative Group","volume":"60","author":"Hermine","year":"2022","journal-title":"Eur Respir J"},{"key":"10.1016\/j.cmi.2022.07.008_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2022.101362","article-title":"Tocilizumab plus dexamethasone versus dexamethasone in patients with moderate-to-severe COVID-19 pneumonia: a randomised clinical trial from the CORIMUNO-19 study group","volume":"46","author":"Hermine","year":"2022","journal-title":"eClinicalMedicine"},{"key":"10.1016\/j.cmi.2022.07.008_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/S2213-2600(22)00006-6","article-title":"Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial","volume":"10","author":"Ely","year":"2022","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib55","series-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis","author":"Horby","year":"2022"},{"key":"10.1016\/j.cmi.2022.07.008_bib41","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib56","doi-asserted-by":"crossref","first-page":"e24","DOI":"10.1016\/S2665-9913(21)00315-5","article-title":"Sarilumab in adults hospitalised with moderate-to-severe COVID-19 pneumonia (CORIMUNO-SARI-1): an open-label randomised controlled trial","volume":"4","author":"Mariette","year":"2022","journal-title":"Lancet Rheumatol"},{"key":"10.1016\/j.cmi.2022.07.008_bib57","doi-asserted-by":"crossref","first-page":"2735","DOI":"10.1007\/s40121-021-00543-2","article-title":"Efficacy and safety of sarilumab in patients with COVID19 pneumonia: a randomized, phase III clinical trial (SARTRE Study)","volume":"10","author":"Sancho-L\u00f3pez","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.cmi.2022.07.008_bib58","article-title":"Efficacy and safety of sarilumab in hospitalized patients with COVID-19: a randomized clinical trial [e-pub ahead of print]","author":"Sivapalasingam","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.cmi.2022.07.008_bib59","doi-asserted-by":"crossref","first-page":"e02107","DOI":"10.1128\/aac.02107-21","article-title":"Early use of sarilumab in patients hospitalized with COVID-19 pneumonia and features of systemic inflammation: the SARICOR Randomized Clinical Trial","volume":"66","author":"Merchante","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.cmi.2022.07.008_bib60","series-title":"Coronavirus disease 2019 (COVID-19) treatment guidelines","year":"2022"},{"key":"10.1016\/j.cmi.2022.07.008_bib61","doi-asserted-by":"crossref","DOI":"10.1136\/bmjmed-2021-000036","article-title":"Use of tocilizumab and sarilumab alone or in combination with corticosteroids for covid-19: systematic review and network meta-analysis","volume":"1","author":"Zeraatkar","year":"2022","journal-title":"BMJ Med"},{"key":"10.1016\/j.cmi.2022.07.008_bib62","doi-asserted-by":"crossref","first-page":"j573","DOI":"10.1136\/bmj.j573","article-title":"Meta-analytical methods to identify who benefits most from treatments: daft, deluded, or deft approach?","volume":"356","author":"Fisher","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.cmi.2022.07.008_bib63","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1002\/sim.1187","article-title":"How should meta-regression analyses be undertaken and interpreted?","volume":"21","author":"Thompson","year":"2002","journal-title":"Stat Med"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200372X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X2200372X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T07:32:34Z","timestamp":1761118354000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X2200372X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":63,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2023,1]]}},"alternative-id":["S1198743X2200372X"],"URL":"https:\/\/doi.org\/10.1016\/j.cmi.2022.07.008","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of tocilizumab, sarilumab, and baricitinib on mortality among patients hospitalized for COVID-19 treated with corticosteroids: a systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Microbiology and Infection","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cmi.2022.07.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}